Overview

Interventional Oncology Market Overview:

Interventional Oncology Market is estimated to value over USD 2 billion by 2027 end and register a CAGR of over 5.9% during the forecast period 2020-2027.

Interventional oncology deals with image guidance carrying minimally invasive medical procedures for diagnosis, palliation and treatment of various cancer types. Various image-guiding techniques like fluoroscopy, ultrasound and computed tomography are implemented in interventional oncology procedures to treat and diagnose a particular site that is affected with cancer or pain. This procedure is often performed with other cancer treatments like chemotherapy, radiation therapy and surgery. Interventional oncological procedures offer multiple advantages like shorter hospital stays, quick recovery, more precise treatment and minimal side effects. 

Technological advancements in interventional oncology, advantages of minimally invasive surgical procedures and increase in the funds offered by the government are some factors that have assisted in the proliferation of the market. 

Product-wise, the market is fragmented into embolization devices, non-radioactive embolic agents, ablation devices, support devices and guidewires. The ablation devices segment is further segmented into radiofrequency ablation devices, microwave ablation devices, cryoablation devices. The embolization devices segment is anticipated to register a remarkable CAGR during the forecast period. The process of embolization has multiple benefits which is why it is primarily preferred worldwide. It is the process of embolus lodging inside the bloodstream to block the blood supply to the tumour. The blood vessels are selectively occluded by introducing emboli using irradiation or chemical techniques. 

Another widely used interventional oncology technique is radiotherapy which is used for treating rare diseases like thyroid, to restrict non-cancerous cell growth and blood disorders.  Radiotherapy is the process that involves radiation through heat or light energy. This segment has immense potential and it is expected to showcase significant market growth during the forecast period.

Based on the type of cancer, the market is bifurcated into renal cancer, lung cancer, kidney cancer, bone cancer, hepatocellular carcinoma, osteosarcoma and other cancers. The liver cancer segment is anticipated to witness remarkable market growth during the forecast period owing to the technological advancements in ablation and embolization devices. 

The market is regionally fragmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. The European and North American regions are expected to showcase significant market growth over the forecast period owing to an increasing cancer patient population. Furthermore, well-established health care infrastructure, effective cancer management, increasing adoption of minimally invasive surgical procedures are some of the key factors responsible for the proliferation of the market. 

The key players operating in the market include:

Medtronic, Boston Scientific, BTG Plc., Terumo, Merit Medical, Sirtex, Ethicon, Cook Medical, Teleflex, HealthTronics, MedWaves Medical, IceCure Medical, Interface Biomaterial BV, Mermaid Medicals, ABK Biomedical, Guerbet, Endo Shape, Instylla, Shape Memory Medical, Monteris Medical and Trisalus Lifesciences.

Market Segmentation:

By Product

• Embolization Devices
• Non-Radioactive Embolic Agents
• Ablation Devices
• Radiofrequency Ablation Devices
• Microwave Ablation Devices
• Cryoablation Devices
• Support Devices

• Guidewires

By Procedure

• Thermal Tumour Ablation
• Non-thermal Tumour Ablation
• Transcatheter Arterial Chemoembolization
• Transcatheter Arterial Radioembolization/Selective Internal Radiation Therapy
• Transcatheter Arterial Embolization/Bland Embolization

By Cancer Type

• Liver Cancer
• Lung Cancer
• Bone Cancer
• Kidney Cancer
• Other Cancers

By Region

• North America
• Europe
• Asia Pacific
• Latin America

• Middle East & Africa

Competitive Landscape:

• Tier 1 players- established companies in the market with a major market share  
• Tier 2 players 
• Emerging players which are growing rapidly 
• New Entrants

FutureWise Key Takeaways:

• Growth prospects for market 
• SWOT analysis  
• Key trends
• Key data-points affecting market growth  

Objectives of the Study:

• To provide with an exhaustive analysis on the market by product, by procedure, by cancer type and by region
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market 
• To predict the market size, in key regions (along with countries)— North America, Asia Pacific, Europe, Latin America and Middle East & Africa
• To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions
• Profiling of companies to evaluate their market shares, strategies, financials and core competencies

Table of Contents

 Introduction 
    1.1 Objectives of the Study 
    1.2 Market Definition 
    1.3 Market Scope 
           1.3.1 Markets Covered
           1.3.2 Years Considered for the Study
    1.4 Currency 
    1.5 Stakeholders 

2 Research Methodology
    2.1 Research Data 
           2.1.1 Secondary Data
                    2.1.1.1 Key Data From Secondary Sources
           2.1.2 Primary Data
                    2.1.2.1 Key Data From Primary Sources
    2.2 Market Size Estimation 
           2.2.1 Product-Based Market Estimation
           2.2.2 Primary Research Validation
    2.3 Market Breakdown and Data Triangulation 
    2.4 Research Limitations and Assumptions 
           2.4.1 Limitations
           2.4.2 Assumptions

3 Executive Summary 

    3.1 Market Outlook
    3.2 Segment Outlook
    3.3 Competitive Insights

4 Premium Insights 
    4.1 Interventional Oncology: Market Overview 
    4.2 Geographic Analysis: Market, By Product 
    4.3 Asia Pacific: Ablation Devices Market, By Type (2019) 
    4.4 Europe: Market, By Cancer Type (2019) 
    4.5 Market, By Procedure, 2020 vs 2025 (USD Million) 
    4.6 Geographical Snapshot of the Market 

5 Market Overview 
    5.1 Introduction 
    5.2 Market Dynamics 
           5.2.1 Drivers
                    5.2.1.1 Rising Patient Preference for Minimally Invasive Procedures
                    5.2.1.2 Expansion of the Target Patient Population
                    5.2.1.3 Increasing Public-Private Funding and Government Support for Interventional Oncology
                    5.2.1.4 Technological Advancements in Interventional Oncology
           5.2.2 Restraints
                    5.2.2.1 Dearth of Well-Trained and Skilled Radiologists and Oncologists
                    5.2.2.2 Unfavorable Regulations
           5.2.3 Opportunities
                    5.2.3.1 Emerging Economies Offer High Growth Potential
                    5.2.3.2 Rising Awareness About the Benefits of Interventional Oncology
           5.2.4 Challenges
                    5.2.4.1 Limited Clinical Data to Support Therapeutic Efficacy
                    5.2.4.2 Strong Market Positioning of Alternative Therapies
    5.3 Market Trends 
           5.3.1 Personalized Or Precision Interventional Oncology

6 Interventional Oncology Market, By Product 
    6.1 Introduction 
    6.2 Embolization Devices 
           6.2.1 Interventional Oncology Embolization Devices Market Split, By Procedure
           6.2.2 Interventional Oncology Embolization Devices Market Split, By Cancer Type
           6.2.3 Radioembolic Agents
                    6.2.3.1 Radioembolic Agents Dominated the Interventional Oncology Embolization Devices Market in 2019
                               6.2.3.1.1 Radioembolic Agents Market Split, By Procedure
                               6.2.3.1.2 Radioembolic Agents Market Split, By Cancer Type
           6.2.4 Non-Radioactive Embolic Agents
                    6.2.4.1 Embolization Procedures Cannot Be Used to Treat Cancers in Advanced Stages, Which is A Major Factor Restraining Market Growth
                               6.2.4.1.1 Non-Radioactive Embolic Agents Market Split, By Procedure
                               6.2.4.1.2 Non-Radioactive Embolic Agents Market Split, By Cancer Type
    6.3 Ablation Devices 
           6.3.1 Technological Advancements in Ablation Devices—A Key Driver for Market Growth
                    6.3.1.1 Interventional Oncology Ablation Devices Market Split, By Procedure
                    6.3.1.2 Interventional Oncology Ablation Devices Market Split, By Cancer Type
           6.3.2 Radiofrequency (RF) Ablation Devices
                    6.3.2.1 Growing Competition Among Different Technologies Offered By Key Players, Backed By Long-Term Clinical Efficacy Data, to Drive the RF Ablation Devices Market
                               6.3.2.1.1 Radiofrequency Ablation Devices Market Split, By Procedure
                               6.3.2.1.2 Radiofrequency Ablation Devices Market Split, By Cancer Type
           6.3.3 Microwave Ablation Devices
                    6.3.3.1 Microwave Ablation Enables the Simultaneous Treatment of Multiple Lesions—A Key Factor Driving Market Growth
                               6.3.3.1.1 Microwave Ablation Devices Market Split, By Procedure
                               6.3.3.1.2 Microwave Ablation Devices Market Split, By Cancer Type
           6.3.4 Cryoablation Devices
                   

6.3.4.1 Advantages of Cryoablation Over Other Thermal Ablation Techniques to Drive Market Growth in the Coming Years
                               6.3.4.1.1 Cryoablation Devices Market Split, By Procedure
                               6.3.4.1.2 Cryoablation Devices Market Split, By Cancer Type
           6.3.5 Other Ablation Devices
                    6.3.5.1 Other Ablation Devices Market Split, By Procedure
                    6.3.5.2 Other Ablation Devices Market Split, By Cancer Type
    6.4 Support Devices 
           6.4.1 Interventional Oncology Support Devices Market Split, By Procedure
           6.4.2 Interventional Oncology Support Devices Market Split, By Cancer Type
           6.4.3 Microcatheters
                    6.4.3.1 Regulatory Approvals Driving the Growth of the Microcatheters Market
                               6.4.3.1.1 Microcatheters Market Split, By Procedure
                               6.4.3.1.2 Microcatheters Market Split, By Cancer Type
           6.4.4 Guidewires
                    6.4.4.1 Advancements in Guidewire Construction and the Launch of New and Advanced Products are the Major Factors Driving the Growth of This Market
                               6.4.4.1.1 Guidewires Market Split, By Procedure
                               6.4.4.1.2 Guidewires Market Split, By Cancer Type

7 Interventional Oncology Market, By Procedure 
    7.1 Introduction 
    7.2 Thermal Tumor Ablation 
           7.2.1 Increasing Clinical Evidence is A Major Factor Driving Market Growth
    7.3 Non-Thermal Tumor Ablation 
           7.3.1 Nanoknife has Emerged as A Potential Alternative to Thermal Tumor Ablation Techniques
    7.4 Transcatheter Arterial Chemoembolization 
           7.4.1 Ability to Treat Small and Large-Sized Tumors – A Major Factor Driving the Demand for Tace Procedures
    7.5 Transcatheter Arterial Radioembolization/Selective Internal Radiation Therapy 
           7.5.1 Tare Shows Greater Clinical Efficacy as Compared to Tace
    7.6 Transcatheter Arterial Embolization/Bland Embolization 
           7.6.1 Increasing Clinical Evidence for Tare and Tace to Restrain Growth of This Market

8 Interventional Oncology Market, By Cancer Type

    8.1 Introduction 
           8.1.1 Liver Cancer
                    8.1.1.1 Increasing Disease Prevalence and Rising Research Activity are Driving Market Growth
           8.1.2 Lung Cancer
                    8.1.2.1 Increasing Number of Cancer Cases Will Drive the Demand for Interventional Oncology Procedures
           8.1.3 Bone Cancer
                    8.1.3.1 Interventional Oncology Procedures Can Eliminate Tumors Directly and Relieve Pain
           8.1.4 Kidney Cancer
                    8.1.4.1 Interventional Oncology Procedures are Appropriate for Patients With A Genetic Disposition for Multiple Tumors
           8.1.5 Other Cancers

9 Interventional Oncology Market, By Region 
    9.1 Introduction 
    9.2 North America 
           9.2.1 US
                    9.2.1.1 US to Dominate the North American Market
           9.2.2 Canada
                    9.2.2.1 Public-Private Initiatives to Support the Adoption of Interventional Oncology Procedures in Canada
    9.3 Europe 
           9.3.1 Germany
                    9.3.1.1 Germany is the Fastest-Growing Market in Europe
           9.3.2 UK
                    9.3.2.1 Increasing Awareness and Support for Cancer-Related Activities to Drive Market Growth in the UK
           9.3.3 France
                    9.3.3.1 Radiofrequency Ablation Dominated the Ablation Devices Market in France
           9.3.4 Rest of Europe
    9.4 Asia Pacific 
           9.4.1 Japan
                    9.4.1.1 Rising Geriatric Population and Universal Healthcare Reimbursement are the Major Driving Factors
           9.4.2 China
                    9.4.2.1 Increasing Cancer Incidence and Growing Patient Population to Drive Market Growth in China
           9.4.3 India
                    9.4.3.1 Improving Research Capabilities Coupled With the Expansion of Key Players to Drive Market Growth in India
           9.4.4 Rest of Asia Pacific
    9.5 Latin America 
           9.5.1 Brazil
                    9.5.1.1 Brazil to Account for the Largest Share of the Latin American Market
           9.5.2 Mexico
                    9.5.2.1 Growing Awareness Campaigns and Rising Incidence of Cancer to Drive Market Growth in Mexico
           9.5.3 Rest of Latin America
    9.6 Middle East and Africa 
           9.6.1 Improving Healthcare Infrastructure and Rising Incidence of Cancer are Driving Growth in the Middle East and Africa

10 Competitive Landscape 
     10.1 Overview 
     10.2 Global Market Share Analysis, 2018 
     10.3 Competitive Scenario (2016 - 2020) 
             10.3.1 Key Product Launches
             10.3.2 Key Acquisitions
             10.3.3 Key Agreements and Collaborations
     10.4 Vendor Dive Overview 
     10.5 Vendor Inclusion Criteria 
     10.6 Vendor Dive 
             10.6.1 Vanguards
             10.6.2 Innovators
             10.6.3 Dynamic Differentiators
             10.6.4 Emerging Companies

11 Company Profiles 
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, FutureWise View)*
     11.1 Healthtronics, Inc. 
     11.2 Trod Medical 
     11.3 Sanarus Technologies, Inc. 
     11.4 Teleflex, Inc. 
     11.5 Imbiotechnologies Ltd. 
     11.6 Medwaves, Inc. 
     11.7 Icecure Medical 
     11.8 Terumo Corporation 
     11.9 Medtronic PLC 
     11.10 BTG PLC 
     11.11 Johnson & Johnson 
     11.12 Merit Medical Systems, Inc. 
     11.13 Boston Scientific Corporation 
     11.14 Angiodynamics, Inc. 
     11.15 Cook Medical 

*Details on FutureWise View, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments Might Not Be Captured in Case of Unlisted Companies.

Tables

Figures